Clinical Trials Logo

Clinical Trial Summary

Dose escalation 3+3 design with accelerated titration 4 dose levels


Clinical Trial Description

This is a 28-day open-label dose-escalation study. TTHX1114(NM141) Ophthalmic Solution: 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days. Four planed dose levels, accelerated titration DL1 and DL2, standard 3+3 design. ;


Study Design


NCT number NCT05769920
Study type Interventional
Source Trefoil Therapeutics, Inc.
Contact
Status Completed
Phase Phase 1
Start date December 6, 2022
Completion date April 12, 2023